Physician profile
Daniel R Harber
NPI 1861472714
$5,182.99
in general payments reported to CMS, 2019-2025
28 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,606 · 2020: $892 · 2021: $608 · 2022: $707 · 2023: $515 · 2024: $686 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,368.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $931.33 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $676.59 | 2020-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $451.50 | 2019-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $417.22 | 2019-2024 | Xarelto |
| United Therapeutics Corporation | $319.92 | 2019-2024 | Tyvaso |
| Pfizer INC. | $295.18 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.86 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $238.36 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $227.66 | 2020-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $192.12 | 2021-2023 | Verquvo |
| Abbott Laboratories | $178.36 | 2022-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Amgen INC. | $163.15 | 2019-2024 | Repatha |
| Actelion Pharmaceuticals US, INC. | $129.26 | 2019-2020 | |
| Edwards Lifesciences Corporation | $100.93 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lundbeck LLC | $93.19 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $92.95 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.33 | 2019-2024 | |
| Boston Scientific Corporation | $82.69 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $42.93 | 2019 | |
| Preventice Services, LLC | $30.92 | 2019-2021 | |
| Novo Nordisk INC | $28.67 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $27.14 | 2021 | |
| Smith+Nephew, INC. | $24.79 | 2019 | |
| Esperion Therapeutics, INC. | $14.78 | 2024 | Nexletol |
| Gilead Sciences, INC. | $13.62 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $13.40 | 2024 | Arcalyst |
| Inari Medical, INC. | $13.30 | 2021 | |
| Astellas Pharma US INC | $12.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Harber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.